Selling, General, and Administrative Costs: United Therapeutics Corporation vs Soleno Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. United Therapeutics Corporation and Soleno Therapeutics, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses from 2014 to 2023.

United Therapeutics Corporation

United Therapeutics has consistently maintained a robust SG&A expenditure, peaking at approximately $487 million in 2022. This represents a steady increase of around 28% from their 2014 figures. Such investment underscores their commitment to expansive marketing and administrative strategies, likely fueling their market dominance.

Soleno Therapeutics, Inc.

Conversely, Soleno Therapeutics, Inc. has shown a more modest SG&A growth, with expenses rising from about $2.9 million in 2014 to $13.5 million in 2023. This nearly 364% increase reflects their strategic scaling efforts, aiming to enhance their market presence.

This comparative analysis highlights the diverse financial strategies within the pharmaceutical sector, offering insights into how companies allocate resources to drive growth and innovation.